Skip to main content

Animations

Illustrated close up of DNA.

Research Tools Catalog

To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.

Helpful Resources

  • Illustrated adjacent hexagons.

    Sponsored Tools Program

    Learn more about how MJFF can help share your tools.

  • Illustrated Parkinson's Disease Research Tools Consortium logo.

    Tools Consortium

    MJFF is working with industry to develop priority tools.

  • Illustrated brain on a presentation display.

    Preclinical Models

    Learn more about the various in vivo models used in Parkinson's disease research.

Find a Research Tool

Filter by Tool Type or Gene/Protein Type to Organize Results

* = MJFF does not control pricing or terms of availability for this tool. 

Filters
  • ${value}
  • PDGFβ-Human Alpha Synuclein (Line D) Mouse*

    Mice express wildtype human alpha synuclein cDNA driven by the platelet derived growth factor, β polypeptide (PDGFB) promoter. Model was developed by Eliezer Masliah and deposited by Robert Rissman at University of California San Diego, and made available through the MJFF Sponsored Tools Program. RRID:IMSR_JAX:038774

  • Ubiquitin pS65 Phosphospecific Antibody (IHC)

    Rabbit monoclonal phosphospecific antibody directed against Serine65 of ubiquitin. Suitable for immunohistochemistry applications. 

  • iNDI-PD iPSCs

    iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) lines are available at JAX. These lines were developed in partnership with NIH, Chan Zuckerberg Initiative, and Aligning Science Across Parkinson's (ASAP) to include iPSC lines expressing PD-associated mutations in SCNA, LRRK2, GBA, PINK1 and PRKN as well as mutation-corrected isogenic revertant controls. An inventory of available lines can be found here: https://www.jax.org/jax-mice-and-services/ipsc/cells-collection

  • iMCI-PARK Mouse*

    Inducible MCI-PARK (iMCI-PARK) mice, based on the ESR-NDUFS2 strain described by Fernández-Agüera, 2015, were generated by crossing mice carrying a floxed allele of mouse Ndufs2 with mice that broadly express tamoxifen-inducible cre recombinase (Tg(CAG-cre/Esr1*)5Amc that result in a conditional, body-wide knock-out of Ndufs2 following tamoxifen induction. Model was originally designed by deleting Ndufs2 only from dopaminergic neurons by D. James Surmeier at Northwestern University and made available through the MJFF Sponsored Tools Program. RRID:IMSR_JAX:038571

  • Parkin KO x Polg Mutator Mouse*

    Parkin KO x Polg Mutator mice were generated by crossing PolgAD257A mutant mice, lacking mitochondria polymerase proofreading function, with Parkin KO mice. Model was designed by Kelly Stauch and Howard Fox at University of Nebraska Medical Center and made available through the MJFF Sponsored Tools Program. RRID:IMSR_JAX:036670

  • MCU Floxed DAT-Cre Mouse*

    MCU Floxed DAT-Cre mice were generated by crossing floxed exons 5 and 6 of the MCU gene (Zampese et al. 2022) with mice expressing Cre recombinase under the dopaminergic-specific DAT to induce knock-out of MCU (mitochondrial Ca2+ uniporter), resulting in the loss of MCU specifically in dopaminergic cells. Model was designed by D. James Surmeier at Northwestern University and made available through the MJFF Sponsored Tools Program. RRID:IMSR_JAX:038988

  • MHC-I H2-Kb Antibody

    Rabbit monoclonal antibody directed against mouse MHC-I H2-Kb for immunoblotting and immunostaining applications. 

    Estimated Availability: Early 2025

  • MHC-I H2-Db Antibody

    Rabbit monoclonal antibody directed against mouse MHC-I H2-Db for immunoblotting and immunostaining applications. 

    Estimated Availability: Early 2025

Have questions or need additional information?

Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page. 

"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD Mayo Clinic
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.